Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 3,800 shares at $353.95 ($1.4M) on 2026-01-12, disclosed to the SEC on 2026-01-14.
Open-market sale of $1.4M ALNY by CSO & EVP, Head of Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $353.95 | 39 | $14K | 1.0% |
| 2 | $355.16 | 42 | $15K | 1.1% |
| 3 | $356.09 | 41 | $15K | 1.0% |
| 4 | $357.17 | 96 | $34K | 2.5% |
| 5 | $358.18 | 123 | $44K | 3.2% |
| 6 | $359.14 | 85 |
| $31K |
| 2.2% |
| 7 | $360.22 | 155 | $56K | 4.0% |
| 8 | $361.45 | 98 | $35K | 2.5% |
| 9 | $362.38 | 73 | $26K | 1.9% |
| 10 | $363.55 | 47 | $17K | 1.2% |
| 11 | $364.83 | 199 | $73K | 5.2% |
| 12 | $365.56 | 220 | $80K | 5.8% |
| 13 | $366.41 | 50 | $18K | 1.3% |
| 14 | $367.40 | 41 | $15K | 1.1% |
| 15 | $368.62 | 92 | $34K | 2.4% |
| 16 | $369.48 | 40 | $15K | 1.1% |
| 17 | $370.87 | 19 | $7K | 0.5% |
| 18 | $372.46 | 2 | $745 | 0.1% |
| 19 | $374.44 | 14 | $5K | 0.4% |
| 20 | $375.65 | 19 | $7K | 0.5% |
| 21 | $377.82 | 15 | $6K | 0.4% |
| 22 | $367.52 | 197 | $72K | 5.2% |
| 23 | $368.76 | 562 | $207K | 14.8% |
| 24 | $370.00 | 644 | $238K | 17.1% |
| 25 | $371.24 | 485 | $180K | 12.9% |
| 26 | $372.93 | 280 | $104K | 7.5% |
| 27 | $374.33 | 122 | $46K | 3.3% |
| Total | $367.37 avg | 3,800 | $1.4M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |
| ALNY | SELL | 2025-10-03 | $2.1M | — | Filing → |